

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

DS

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/11, C07K 14/47, A61K 38/17, C07K 16/18, C12N 9/64	A1	(11) International Publication Number: WO 96/40907 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/06363 (22) International Filing Date: 6 May 1996 (06.05.96) (30) Priority Data: 08/487,942 7 June 1995 (07.06.95) US (71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). (72) Inventors: LIN, Lih-Ling; 107 College Road, Concord, MA 01742 (US). GRAHAM, James; 28 Foscett Street, Somerville, MA 02144 (US). (74) Agent: BROWN, Scott, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).		(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> COPY
(54) Title: INTERLEUKIN-1 RECEPTOR INTRACELLULAR LIGAND PROTEINS AND INHIBITORS OF LIGAND BINDING (57) Abstract Novel IL-1-R intracellular ligand proteins are disclosed. Polynucleotides encoding the IL-1-R intracellular ligand protein are also disclosed, along with vectors, host cells, and methods of making the IL-1-R intracellular ligand protein. Pharmaceutical compositions containing the IL-1-R intracellular ligand protein, methods of treating inflammatory conditions, and methods of inhibiting IL-1-R intracellular domain binding are also disclosed. Methods of identifying inhibitors of IL-1-R intracellular domain binding and inhibitors identified by such methods are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5 INTERLEUKIN-1 RECEPTOR INTRACELLULAR LIGAND PROTEINS
AND INHIBITORS OF LIGAND BINDING

BACKGROUND OF THE INVENTION

10 The present invention relates to the field of anti-inflammatory substances and other substances which act, by inhibiting binding to the intracellular domain of an interleukin-1 receptor (hereinafter "IL-1-R"), such as, for example, the p80, type I IL-1 receptor. More particularly, the present invention is directed to novel ligands which bind to the IL-1-R intracellular domain and to inhibition or modulation of
15 signal transduction by this receptor.

Interleukin-1- α and interleukin-1- β (herein collectively "IL-1") are cytokines which produce a wide range of cellular activities. IL-1 causes an inflammatory response, which can be beneficial, such as in mounting an immune response to a pathogen, or when overexpressed can lead to other detrimental effects of
20 inflammation.

The cellular effects of IL-1 are initiated by the binding of IL-1 to its receptors (IL-1-Rs) on the surface of target cells. The isolation of polynucleotides encoding IL-1-Rs and variant forms of such receptors has been described in U.S. Patent Nos. 4,968,607, 5,081,228, 5,180,812, in PCT Publication No. WO91/18982,
25 and by Sims et al., PNAS, 86, 8946 (1989) (disclosing the p80, type I IL-1 receptor). Processes for purification of IL-1-Rs have also been disclosed in U.S. Patent No. 5,296,592.

Native IL-1-Rs are characterized by distinct extracellular, transmembrane and intracellular domains. The primary purpose of the extracellular domain is to present
30 a binding site for IL-1 on the outside of the cell. When IL-1 is bound to the binding site, a "signal" is transmitted to the inside of the cell through the transmembrane and intracellular domains, indicating that binding has occurred. Transmission or "transduction" of the signal to the inside of the cell occurs by a change in conformation of the transmembrane and/or intracellular domains of the receptor.
35 This signal is "received" by the binding of proteins and other molecules to the intracellular domain of the receptor, resulting in the effects seen upon IL-1 stimulation.

While IL-1 binding by IL-1-Rs results in beneficial cellular effects, it is often desirable to prevent or deter IL-1 binding from causing other detrimental cellular effects. Although substantial effort has been expended investigating inhibition of IL-1 binding to the extracellular domain of IL-1-Rs, examination of binding of proteins and other molecules to the intracellular domain of IL-1-Rs has received much less attention.

However, ligands which bind to the IL-1-R intracellular domain have yet to be identified. It would be desirable to identify and isolate such ligands to examine their effects upon IL-1-R signal transduction and their use as therapeutic agents for treatment of IL-1-induced conditions. Furthermore, identification of such ligands would provide a means for screening for inhibitors of IL-1-R/intracellular ligand binding, which will also be useful as anti-inflammatory agents.

SUMMARY OF THE INVENTION

Applicants have for the first time identified novel IL-1-R intracellular ligand proteins and have isolated polynucleotides encoding such ligands. Applicants have also identified certain known proteins which may also bind to the intracellular domain of IL-1-R.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide encoding a protein having IL-1-R intracellular ligand protein activity. In preferred embodiments, the polynucleotide is selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 2 to nucleotide 529;
- (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:1, which encodes a protein having IL-1-R intracellular ligand protein activity;
- (c) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:2;
- (d) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 and having IL-1-R intracellular ligand protein activity;

(e) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 2 to nucleotide 961;

(f) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:3, which encodes a protein having IL-1-R intracellular ligand protein activity;

(g) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:4;

(h) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 and having IL-1-R intracellular ligand protein activity;

(i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 2 to nucleotide 754;

(j) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:5, which encodes a protein having IL-1-R intracellular ligand protein activity;

(k) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:6;

(l) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 and having IL-1-R intracellular ligand protein activity; and

(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(l), which encodes a protein having IL-1-R intracellular ligand protein activity.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.

Processes are also provided for producing an IL-1-R intracellular ligand protein, which comprises:

(a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and

(b) purifying the IL-1-R intracellular ligand protein from the culture.

The ligand protein produced according to such methods is also provided by the present invention.

5 Compositions comprising a protein having IL-1-R intracellular ligand protein activity are also disclosed. In preferred embodiments the protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) fragments of the amino acid sequence of SEQ ID NO:2;
- 10 (c) the amino acid sequence of SEQ ID NO:4;
- (d) fragments of the amino acid sequence of SEQ ID NO:4;
- (e) the amino acid sequence of SEQ ID NO:6; and
- (f) fragments of the amino acid sequence of SEQ ID NO:6;

the protein being substantially free from other mammalian proteins. Such
15 compositions may further comprise a pharmaceutically acceptable carrier.

Compositions comprising an antibody which specifically reacts with such IL-1-R intracellular ligand protein are also provided by the present invention.

Methods are also provided for identifying an inhibitor of IL-1-R intracellular domain binding which comprise:

- 20 (a) combining an IL-1-R intracellular domain protein with an IL-1-R intracellular ligand protein, said combination forming a first binding mixture;
- (b) measuring the amount of binding between the IL-1-R intracellular domain protein and the IL-1-R intracellular ligand protein in the
25 first binding mixture;
- (c) combining a compound with the IL-1-R intracellular domain protein and an IL-1-R intracellular ligand protein to form a second binding mixture;
- (d) measuring the amount of binding in the second binding
30 mixture; and
- (e) comparing the amount of binding in the first binding mixture with the amount of binding in the second binding mixture;

wherein the compound is capable of inhibiting IL-1-R intracellular domain binding when a decrease in the amount of binding of the second binding mixture occurs. In certain preferred embodiments the IL-1-R intracellular ligand protein used in such method comprises an amino acid sequence selected from the group consisting of:

- 5 (a) the amino acid sequence of SEQ ID NO:2;
- (b) fragments of the amino acid sequence of SEQ ID NO:2;
- (c) the amino acid sequence of SEQ ID NO:4;
- (d) fragments of the amino acid sequence of SEQ ID NO:4;
- (e) the amino acid sequence of SEQ ID NO:6;
- 10 (f) fragments of the amino acid sequence of SEQ ID NO:6;
- (g) the amino acid sequence of SEQ ID NO:7; and
- (h) fragments of the amino acid sequence of SEQ ID NO:7.

Compositions comprising inhibitors identified according to such method are also provided. Such compositions may include pharmaceutically acceptable carriers.

- 15 Methods are also provided for preventing or ameliorating an inflammatory condition which comprises administering a therapeutically effective amount of a composition comprising a protein having IL-1-R intracellular ligand protein activity and a pharmaceutically acceptable carrier.

Other embodiments provide methods of inhibiting IL-1-R intracellular domain
20 binding comprising administering a therapeutically effective amount of a composition comprising a protein having IL-1-R intracellular ligand protein activity and a pharmaceutically acceptable carrier.

Methods of preventing or ameliorating an inflammatory condition or of inhibiting IL-1-R intracellular domain binding are provided, which comprise
25 administering to a mammalian subject a therapeutically effective amount of inhibitors of IL-1-R intracellular domain binding, are also provided.

Methods of identifying an inhibitor of IL-1-R intracellular domain binding are also provided by the present invention which comprise:

- 30 (a) transforming a cell with a first polynucleotide encoding an IL-1-R intracellular domain protein, a second polynucleotide encoding an IL-1-R intracellular ligand protein, and at least one reporter gene, wherein the expression of the reporter gene is regulated by the binding of the IL-1-R

intracellular ligand protein encoded by the second polynucleotide to the IL-1-R intracellular domain protein encoded by the first polynucleotide;

(b) growing the cell in the presence of and in the absence of a compound; and

5 (c) comparing the degree of expression of the reporter gene in the presence of and in the absence of the compound;

wherein the compound is capable of inhibiting IL-1-R intracellular domain binding when a decrease in the degree of expression of the reporter gene occurs. In preferred embodiments, the cell is a yeast cell and the second polynucleotide is selected from

10 the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 2 to nucleotide 529;

(b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:1, which encodes a protein having IL-1-R intracellular ligand protein activity;

15 (c) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:2;

(d) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 and having IL-1-R intracellular ligand protein activity;

20 (e) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 2 to nucleotide 961;

(f) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:3, which encodes a protein having IL-1-R intracellular ligand protein activity;

25 (g) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:4;

(h) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 and having IL-1-R intracellular ligand protein activity;

30 (i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 2 to nucleotide 754;

(j) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:5, which encodes a protein having IL-1-R intracellular ligand protein activity;

5 (k) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:6;

(l) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 and having IL-1-R intracellular ligand protein activity;

10 (m) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:7;

(n) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 and having IL-1-R intracellular ligand protein activity; and

15 (o) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(n), which encodes a protein having IL-1-R intracellular ligand protein activity.

BRIEF DESCRIPTION OF THE FIGURES

20 Fig. 1 depicts an autoradiograph demonstrating the expression of IL-1-R intracellular ligand proteins of the present invention in mammalian cells. The expression of flag-14w, -31w and -19w was detected by an anti-flag antibody, M2, as described below.

Fig. 2 demonstrates the effects of the clone 19w product on JNK1 activation. Top panel: HA-tagged JNK1 was coexpressed in COS cells with either pED flag vector or pED flag-19w. After 48 hr, the cells were treated with different concentrations of IL-1 α for 15 min. JNK1 was isolated by immunoprecipitation with 12CA5 antibody and JNK activity was measured using an immune complex kinase assay with the substrate GST-c-jun (1-79). Middle panel: The expression and recovery of HA-JNK1 from immunoprecipitation was examined by Western blot analysis with 12CA5 antibody. Bottom panel: The expression of clone 19w was 30 detected by Western blot analysis of cell lysate using M2 antibody.

DETAILED DESCRIPTION OF THE INVENTION

The present inventors have for the first time identified and isolated novel polynucleotides which encode proteins which bind to the IL-1-R intracellular domain. As used herein "IL-1-R" includes all receptors for interleukin-1. The type I, p80 IL-1-R is the preferred receptor for practicing the present invention.

The sequence of a polynucleotide encoding one such protein is set forth in SEQ ID NO:1 from nucleotide 2 to 529. This polynucleotide has been identified as "clone 19w." The amino acid sequence of the IL-1-R intracellular ligand protein encoded by clone 19w is set forth in SEQ ID NO:2. It is believed that clone 19w is a partial cDNA clone of a longer full length coding sequence. However, as demonstrated herein the protein encoded by clone 19w does bind the intracellular domain of IL-1-R (i.e., has "IL-1-R intracellular ligand protein activity" as defined herein). Clone 19w was deposited with the American Type Culture Collection on March 31, 1995 and given the accession number ATCC 69774. The protein encoded by clone 19w is 176 amino acids in length. No identical or closely related sequences were found using database searches. Therefore, clone 19w encodes a novel protein. However, using an extensive FASTA search, a significant homology to amino acids 330 to 390 of thrombospondin (41% identity in 59 amino acids) is found in the C-terminal portion of the 19w protein. Moreover, a significant homology to the Ca²⁺ binding domain, EF hand of calmodulin (25% in 65 amino acids) is observed in the region between amino acids 40 and 110 of the protein encoded by clone 19w.

The sequence of a polynucleotide encoding another such protein is set forth in SEQ ID NO:3 from nucleotide 2 to 961. This polynucleotide has been identified as "clone 31w." The amino acid sequence of the IL-1-R intracellular ligand protein encoded by clone 31w is set forth in SEQ ID NO:4. It is believed that clone 31w is a partial cDNA clone of a longer full length coding sequence. However, as demonstrated herein the protein encoded by clone 31w does bind the intracellular domain of IL-1-R (i.e., has "IL-1-R intracellular ligand protein activity" as defined herein). Clone 31w was deposited with the American Type Culture Collection on March 31, 1995 and given the accession number ATCC 69775. The protein encoded by clone 31w is 320 amino acids in length. No identical or closely related sequences

were found using BLASTN/BLASTX or FASTA searches. Therefore, clone 31w encodes a novel protein.

The sequence of a polynucleotide encoding another such protein is set forth in SEQ ID NO:5 from nucleotides 2 to 754. This polynucleotide has been identified as "clone 14w." The amino acid sequence of the IL-1-R intracellular ligand protein encoded by clone 14w is set forth in SEQ ID NO:6. It is believed that clone 14w is a partial cDNA clone of a longer full length coding sequence. However, as demonstrated herein the protein encoded by clone 14w does bind the intracellular domain of IL-1-R (i.e., has "IL-1-R intracellular ligand protein activity" as defined herein). Clone 14w was deposited with the American Type Culture Collection on March 31, 1995 and given the accession number ATCC 69773.

The protein encoded by clone 14w is identical to the sequence of amino acids 449 to 700 of calcium activated neutral protease (CANP), with the exception of an amino acid change (Val to Phe) at position 553 of CANP. The sequence of CANP is disclosed in Imajoh et al., Biochemistry 1988, 27, 8122-8128, which is incorporated herein by reference (accession no. A31218). The amino acid sequence of CANP is set forth in SEQ ID NO:7. Based upon this sequence homology, CANP and certain fragments thereof will exhibit IL-1-R intracellular ligand binding activity (as defined herein).

For the purposes of the present application, "IL-1-R intracellular ligand protein" includes proteins which exhibit IL-1-R intracellular ligand protein activity. For the purposes of the present application, a protein is defined as having "IL-1-R intracellular ligand protein activity" when it binds to a protein derived from the IL-1-R intracellular domain. Activity can be measured by using any assay which will detect binding to an IL-1-R intracellular domain protein. Examples of such assays include without limitation the interaction trap assays and assays in which IL-1-R intracellular domain protein which is affixed to a surface in a manner conducive to observing binding, including without limitation those described in Examples 1 and 3. As used herein an "IL-1-R intracellular domain protein" includes the entire intracellular domain or fragments thereof.

Fragments of the IL-1-R intracellular ligand protein which are capable of interacting with the IL-1-R intracellular domain or which are capable of inhibiting

IL-1-R intracellular domain binding (i.e., exhibit IL-1-R intracellular ligand protein activity) are also encompassed by the present invention. Fragments of the IL-1-R intracellular ligand protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, Bio/Technology 5 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of IL-1-R intracellular ligand protein binding sites. For example, fragments of the IL-1-R intracellular ligand protein may be fused 10 through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the IL-1-R intracellular ligand protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, an IL-1-R intracellular ligand protein - IgM fusion would generate a decavalent form of the IL-1-R intracellular ligand protein 15 of the invention.

The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the IL-1-R intracellular ligand protein recombinantly. Many suitable expression control 20 sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and the expression control sequence are situated within a vector or cell in such a way that the IL-1-R intracellular ligand protein is 25 expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the IL-1-R intracellular ligand protein. Host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human 30 epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of

primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

The IL-1-R intracellular ligand protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference.

Alternatively, it may be possible to produce the IL-1-R intracellular ligand protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins. If the IL-1-R intracellular ligand protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional IL-1-R intracellular ligand protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The IL-1-R intracellular ligand protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the IL-1-R intracellular ligand protein.

The IL-1-R intracellular ligand protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the IL-1-R intracellular ligand protein may also include an affinity column

containing the IL-1-R intracellular domain or other IL-1-R intracellular domain protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether,
5 butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the IL-1-R intracellular ligand protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP) or glutathione-S-transferase (GST). Kits for expression and purification of such fusion
10 proteins are commercially available from New England BioLab (Beverly, MA) and Pharmacia (Piscataway, NJ), respectively. The IL-1-R ligand protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, CT).

15 Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the IL-1-R intracellular ligand protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous
20 isolated recombinant protein. The IL-1-R intracellular ligand protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated IL-1-R intracellular ligand protein."

IL-1-R intracellular ligand proteins may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present
25 invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with IL-1-R intracellular ligand proteins may possess biological properties in common therewith, including IL-1-R intracellular ligand protein activity. Thus, they may be employed as biologically
30 active or immunological substitutes for natural, purified IL-1-R intracellular ligand proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The IL-1-R intracellular ligand proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified IL-1-R intracellular ligand proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the IL-1-R intracellular ligand protein sequences may include the replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Mutagenic techniques for such replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584).

Other fragments and derivatives of the sequences of IL-1-R intracellular ligand proteins which would be expected to retain IL-1-R intracellular ligand protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

IL-1-R intracellular ligand protein of the invention may also be used to screen for agents which are capable of inhibiting or blocking binding of an IL-1-R intracellular ligand protein to the intracellular domain of IL-1-R, and thus may act as inhibitors of IL-1-R intracellular domain binding and/or IL-1 activity. Binding assays using a desired binding protein, immobilized or not, are well known in the art and may be used for this purpose using the IL-1-R intracellular ligand protein of the invention. Examples 1 and 3 describe examples of such assays. Appropriate screening assays may be cell-based or cell-free. Alternatively, purified protein based screening assays may be used to identify such agents. For example, IL-1-R intracellular ligand protein may be immobilized in purified form on a carrier and binding to purified IL-1-R intracellular domain may be measured in the presence and in the absence of potential inhibiting agents. A suitable binding assay may alternatively employ purified IL-1-R intracellular domain immobilized on a carrier with a soluble form of a IL-1-R intracellular ligand protein of the invention. Any

IL-1-R intracellular ligand protein may be used in the screening assays described above.

In such a screening assay, a first binding mixture is formed by combining IL-1-R intracellular domain protein and IL-1-R intracellular ligand protein, and the amount of binding in the first binding mixture (B_0) is measured. A second binding mixture is also formed by combining IL-1-R intracellular domain protein, IL-1-R intracellular ligand protein, and the compound or agent to be screened, and the amount of binding in the second binding mixture (B) is measured. The amounts of binding in the first and second binding mixtures are compared, for example, by performing a B/B_0 calculation. A compound or agent is considered to be capable of inhibiting IL-1-R intracellular domain binding if a decrease in binding in the second binding mixture as compared to the first binding mixture is observed. The formulation and optimization of binding mixtures is within the level of skill in the art. Such binding mixtures may also contain buffers and salts necessary to enhance or to optimize binding, and additional control assays may be included in the screening assay of the invention.

Alternatively, appropriate screening assays may be cell based. For example, the binding or interaction between an IL-1-R ligand protein and the IL-1-R intracellular domain can be measured in yeast as described below in Examples 1 and 3.

Compounds found to reduce, preferably by at least about 10%, more preferably greater than about 50% or more, the binding activity of IL-1-R intracellular ligand protein to IL-1-R intracellular domain may thus be identified and then secondarily screened in other binding assays, including *in vivo* assays. By these means compounds having inhibitory activity for IL-1-R intracellular domain binding which may be suitable as anti-inflammatory agents may be identified.

Isolated IL-1-R intracellular ligand protein may be useful in treating, preventing or ameliorating inflammatory conditions and other conditions, such as osteoporosis, colitis, myelogenous leukemia, diabetes, wasting and atherosclerosis. Isolated IL-1-R intracellular ligand protein may be used itself as an inhibitor of IL-1-R intracellular domain binding or to design inhibitors of IL-1-R intracellular domain binding. Inhibitors of binding of IL-1-R intracellular ligand protein to the IL-1-R

intracellular domain ("IL-1-R intracellular binding inhibitors") are also useful for treating such conditions.

The present invention encompasses both pharmaceutical compositions and therapeutic methods of treatment or use which employ isolated IL-1-R intracellular
5 ligand protein and/or binding inhibitors of IL-1-R intracellular binding.

Isolated IL-1-R intracellular ligand protein or binding inhibitors (from whatever source derived, including without limitation from recombinant and non-recombinant cell lines) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in
10 addition to IL-1-R intracellular ligand protein or binding inhibitor and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of
15 administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, G-CSF, Meg-CSF, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other anti-inflammatory agents. Such additional factors and/or agents
20 may be included in the pharmaceutical composition to produce a synergistic effect with isolated IL-1-R intracellular ligand protein or binding inhibitor, or to minimize side effects caused by the isolated IL-1-R intracellular ligand protein or binding inhibitor. Conversely, isolated IL-1-R intracellular ligand protein or binding inhibitor may be included in formulations of the particular cytokine, lymphokine, other
25 hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

The pharmaceutical composition of the invention may be in the form of a liposome in which isolated IL-1-R intracellular ligand protein or binding inhibitor is
30 combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids

for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of an inflammatory response or condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of isolated IL-1-R intracellular ligand protein or binding inhibitor is administered to a mammal having a condition to be treated. Isolated IL-1-R intracellular ligand protein or binding inhibitor may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, isolated IL-1-R intracellular ligand protein or binding inhibitor may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering isolated IL-1-R intracellular ligand protein or binding inhibitor in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of isolated IL-1-R intracellular ligand protein or binding inhibitor used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral

ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of isolated IL-1-R intracellular ligand protein or binding inhibitor is administered orally, isolated IL-1-R intracellular
5 ligand protein or binding inhibitor will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% isolated IL-1-R intracellular ligand protein or binding inhibitor, and preferably from about 25
10 to 90% isolated IL-1-R intracellular ligand protein or binding inhibitor. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols
15 such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of isolated IL-1-R intracellular ligand protein or binding inhibitor, and preferably from about 1 to 50% isolated IL-1-R intracellular ligand protein or binding inhibitor.

20 When a therapeutically effective amount of isolated IL-1-R intracellular ligand protein or binding inhibitor is administered by intravenous, cutaneous or subcutaneous injection, isolated IL-1-R intracellular ligand protein or binding inhibitor will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having
25 due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to isolated IL-1-R intracellular ligand protein or binding inhibitor, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated
30 Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of isolated IL-1-R intracellular ligand protein or binding inhibitor in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will
5 decide the amount of isolated IL-1-R intracellular ligand protein or binding inhibitor with which to treat each individual patient. Initially, the attending physician will administer low doses of isolated IL-1-R intracellular ligand protein or binding inhibitor and observe the patient's response. Larger doses of isolated IL-1-R intracellular ligand protein or binding inhibitor may be administered until the optimal
10 therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 μ g to about 100 mg of isolated IL-1-R intracellular ligand protein or binding inhibitor per kg body weight.

15 The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the isolated IL-1-R intracellular ligand protein or binding inhibitor will be in the range of 12 to 24 hours
20 of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Isolated IL-1-R intracellular ligand protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which
25 specifically react with the IL-1-R intracellular ligand protein and which may inhibit IL-1-R intracellular domain binding. Such antibodies may be obtained using either the entire IL-1-R intracellular ligand protein or fragments of IL-1-R intracellular ligand protein as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as
30 keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987).

Monoclonal antibodies binding to IL-1-R intracellular ligand protein or to complex carbohydrate moieties characteristic of the IL-1-R intracellular ligand glycoprotein may be useful diagnostic agents for the immunodetection of IL-1-R ligand protein.

5 Neutralizing monoclonal antibodies binding to IL-1-R intracellular ligand protein or to complex carbohydrates characteristic of IL-1-R intracellular ligand glycoprotein may also be useful therapeutics for both inflammatory conditions and also in the treatment of some forms of cancer where abnormal expression of IL-1-R intracellular ligand protein is involved. These neutralizing monoclonal antibodies are
10 capable of blocking the signaling function of the IL-1-R intracellular ligand protein. By blocking the binding of IL-1-R intracellular ligand protein, certain biological responses to IL-1 are either abolished or markedly reduced. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against IL-1-R intracellular ligand protein may be useful in detecting and preventing the metastatic
15 spread of the cancerous cells, which may be mediated by the IL-1-R intracellular ligand protein.

Due to the similarity of its sequence to SEQ ID NO:6, CANP and fragments thereof which bind to the IL-1-R intracellular domain are proteins having IL-1-R intracellular ligand protein activity as defined herein. As a result, they are also
20 useful in pharmaceutical compositions, for treating inflammatory conditions and for inhibiting IL-1-R intracellular domain binding as described above for IL-1-R intracellular ligand proteins generally.

EXAMPLE 1

25 CLONING OF IL-1-R INTRACELLULAR LIGAND PROTEIN ENCODING POLYNUCLEOTIDE

A yeast genetic selection method, the "interaction trap" [Gyuris et al, Cell
75:791-803, 1993, which is incorporated herein by reference], was used to screen
30 WI38 and HeLa cell cDNA libraries (preparation, see below) for proteins that interact with IL-1-R-1c, the cytoplasmic portion (intracellular domain) of the interleukin-1 receptor p80, or type I. The IL-1-R-1c DNA, encoding amino acids 340 to 552 of the type I IL-1 receptor, was obtained via the polymerase chain

reaction (PCR) of a human WI38 cell cDNA library. This IL-1-R-1c DNA was then cloned into pEG202 by an EcoRI site, generating the bait plasmid, pEG202-IL-1-R-1c. This plasmid contains the HIS3 selectable marker, and expression of the bait, the LexA-IL-1-R-1c fusion protein, is from the strong constitutive ADH1 promoter. To create the reporter strain carrying the bait protein, yeast strain EGY48, containing the reporter sequence LexAop-Leu2 in place of the chromosomal LEU2, was transformed with pEG202-IL-1-R-1c and pSH18-34 (Ura+), which carries another reporter sequence, LexAop-lacZ. For screening cDNAs encoding proteins that interact with IL-1-R-1c, the expression vector pJG4-5 (TRP1), containing either a WI38 or HeLa cell cDNA library (see below for the cDNA library construction), was transformed into the above strain (EGY48/pEG202-IL-1-R-1c/pSH18-34) according to the method described by Gietz et al., Nucleic Acids Res., 20, 1425, 1992.

The bait used in obtaining clones 14w, 19w and 31w was constructed by cloning the DNA sequences encoding amino acids 477 to 527 of IL-1 receptor p80 into the EcoRI and NotI sites of EG202. The resulting plasmid was named EG202-IL1R (477-527). This region of the IL-1 receptor is believed to be essential for signaling.

cDNA Library Construction:

WI38 cell cDNA library: Double stranded cDNA was prepared from 3 µg of WI38 mRNA using reagents provided by the Superscript Choice System (Gibco/BRL, Gaithersburg, MD) with the following substitutions: the first strand synthesis was primed using an oligo dT/XhoI primer/linker, and the dNTP mix was substituted with a mix containing methyl dCTP (Stratagene, LaJolla, CA). The cDNA was modified at both ends by addition of an EcoRI/NotI/SalI adapter linker and subsequently digested with XhoI. This produced cDNA molecules possessing an EcoRI/NotI/SalI overhang at the 5' end of the gene and an XhoI overhang at the 3' end. These fragments were then ligated into the yeast expression/fusion vector pJG4-5 (Gyuris et al., Cell, 75, 791-803, 1993), which contains at its amino terminus, the influenza virus HA1 epitope tag, the B42 acidic transcription activation domain, and the SV40 nuclear localization signal, all under the control of the

galactose-dependent GAL1 promoter. The resulting plasmids were then electroporated into DH10B cells (Gibco/BRL). A total of 7.1×10^6 colonies were plated on LB plates containing 100 ug/ml of ampicillin. These *E. coli* were scraped, pooled, and a large scale plasmid prep was performed using the Wizard Maxi Prep kit (Promega, Madison, WI), yielding 3.2mg of supercoiled plasmid DNA.

HeLa cell cDNA: HeLa cell cDNA preparation methods are described in Gyuris et al., Cell, 75, 791-803, 1993, which is incorporated herein by reference.

HeLa Cell cDNA Screening Results:

2 x 10^5 transformants were obtained on glucose Ura⁺His⁺Trp⁺ plates. These transformants were pooled and resuspended in a solution of 65% glycerol, 10mM Tris-HCl (pH 7.5), 10 mM MgCl₂ and stored at -80°C in 1mL aliquots. For screening purposes, aliquots of these were diluted 10-fold into Ura⁺His⁺Trp⁺ CM dropout gal/raff medium (containing 2% galactose, 1% raffinose), which induces the expression of the library encoded proteins, and incubated at 30°C for 4 hours. 2 x 10^6 colony forming units (CFUs) were then plated on standard 10cm galactose X-Gal Ura⁺His⁺Trp⁺Leu⁺ plates at a density of 2 x 10^5 CFU/plate. After 4 days at 30°C, colonies that were strong LacZ⁺ were chosen for further processing. In order to test if the Leu⁺/LacZ⁺ phenotype was due to the library-encoded protein, the galactose dependency of the phenotype was tested. Expression of the library-encoded proteins was turned off by growth on glucose Ura⁺His⁺Trp⁺ master plates and then retested for galactose-dependency on glucose Ura⁺His⁺Trp⁺Leu⁺, galactose Ura⁺His⁺Trp⁺Leu⁺, glucose X-Gal Ura⁺His⁺Trp⁺, and galactose X-Gal Ura⁺His⁺Trp⁺ plates. Of these, many colonies showed galactose-dependent growth on Leu⁺ plates and galactose-dependent blue color on X-Gal-containing medium (LacZ⁺ phenotype). Total yeast DNA was prepared from these colonies according to the method described previously (Hoffman and Winston, 1987). In order to analyze the cDNA sequences, PCR reactions were performed using the above yeast DNA as a template and oligo primers specific for the vector pJG4-5, flanking the cDNA insertion point. PCR products were purified (Qiagen PCR purification kit), subjected to restriction digest with the enzyme HaeIII, run on 1.8% agarose gels, and the restriction patterns compared. Similar and identical restriction patterns were grouped and representatives of each group were

sequenced and compared to Genbank and other databases to identify any sequence homologies.

WI38 Cell cDNA Screening Results:

5 This screen was performed as above with the following exceptions: 1) 1×10^6 transformants were obtained on glucose Ura⁺His⁺Trp⁺ plates and pooled. 2) 11×10^6 CFU were screened. Of these, 0.5% were Leu⁺ and of those, 1% were LacZ⁺. This gave a frequency of 50 double positives per 10^6 transformants screened. Colonies, exhibiting a strong LacZ⁺ phenotype (as judged by the strength of blue color on
10 X-Gal containing medium), were chosen for further processing. Clones with the strongest LacZ⁺ phenotype were chosen for further specificity tests as described above.

A WI38 cDNA library was transformed into the reporter strain (EGY48/pSH18-34) containing the bait plasmid EG202-IL1R (477-527). 1.3 million
15 primary transformants were harvested and 7 million colonies were screened. 192 galactose-dependent colonies were isolated. Among these, 51 clones were bait specific (*i.e.*, interacted specifically with the original bait, but not with an unrelated bait, bicoid). These clones were then subjected to DNA sequence analysis. Clones
19w was isolated 6, times, clone 31w twice, and clone 14w once.

20

EXAMPLE 2 EXPRESSION OF THE IL-1-R INTRACELLULAR LIGAND PROTEIN

cDNAs encoding IL-1-R intracellular ligand proteins were released from the
25 pJG4-5 vector with the appropriate restriction enzymes. For example, EcoRI and XhoI were used to release cDNA from the relevant clone. Where the restriction sites were also present in the internal sequence of the cDNA, PCR was performed to obtain the cDNA. These cDNAs were then cloned into various expression vectors. These included pGEX (Pharmacia) or pMAL (New England Biolabs) for expression
30 as a GST (Glutathione-S-transferase) or MBP (maltose binding protein) fusion protein in *E. coli*, a pED-based vector for mammalian expression, and pVL or pBlueBacHis (Invitrogen) for baculovirus/insect expression. For the immunodetection of IL-1-R intracellular ligand expression in mammalian cells, an

epitope sequence, "Flag," was inserted into the translational start site of the pED vector, generating the pED-Flag vector. cDNAs were then inserted into the pED-Flag vector. Thus, the expression of cDNA from pED-Flag yields a protein with an amino terminal Met, followed by the "Flag" sequence, Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys.

5 Standard DEAE-Dextran or lipofectamine methods were used to transfect COS or CHO dukx cells. Immunodetection of Flag-tagged proteins was achieved using the M2 antibody (Kodak). Moreover, an immunoaffinity column using the M2 antibody, followed by elution with the "Flag" peptide, can be used for the rapid purification of the flag-tagged protein. Similarly, affinity purification of GST- , MBP- or

10 His-tagged fusion proteins can be performed using glutathione, amylose, or nickel columns. Detailed purification protocols are provided by the manufacturers. For many fusion proteins, the IL-1-R intracellular ligand can be released by the action of thrombin, factor Xa, or enterokinase cleavage. In the case where highly purified material is required, standard purification procedures, such as ion-exchange,

15 hydrophobic, and gel filtration chromatography will be applied in addition to the affinity purification step.

Fig. 1 depicts an autoradiograph demonstrating the expression of IL-1-R intracellular ligand proteins in mammalian cells. Fig. 1 shows the results of expression of Flag-14w, -19w and -31w in COS cells. COS cells were transfected

20 with either pED-Flag (vector control), Flag-14w, -19w or -31w plasmid by the lipofectamine method. Thirty µg of each cell lysate were prepared and subjected to 4-20% SDS gel electrophoresis, followed by Western blot analysis using M2 antibody (Kodak). A Flag-containing protein, Flag-BAP (Kodak), was also loaded as a standard. The bands in the Flag-14w, -19w and -31w indicate significant expression

25 of the respective IL-1-R intracellular ligand proteins.

EXAMPLE 3

ASSAYS OF IL-1-R INTRACELLULAR DOMAIN BINDING

30 Two different methods were used to assay for IL-1-R intracellular ligand protein activity. The first assay measures binding in the yeast strain in "interaction trap," the system used here to screen for IL-1-R-1c interacting proteins. In this system, the expression of reporter genes from both LexAop-Leu2 and LexAop-LacZ

relies on the interaction between the bait protein, in this case IL-1-R-1c, and the prey, the IL-1-R intracellular ligand. Thus, one can measure the strength of the interaction by the level of Leu2 or LacZ expression. The most simple method is to measure the activity of the LacZ encoded protein, β -galactosidase. This activity can be judged by the degree of blueness on the X-Gal containing medium or filter. For the quantitative measurement of β -galactosidase activity, standard assays can be found in "Methods in Yeast Genetics" Cold Spring Harbor, New York, 1990 (by Rose, M.D., Winston, F., and Hieter, P.).

The second assay for measuring binding is a cell-free system. An example of a typical assay is described below. Purified MBP-IL-1-R-1c fusion protein (2 μ g) was mixed with glutathione-Sepharose 4 B beads bound with a GST-IL-1-R-1c intracellular ligand for 2 hour at 4°C. The mixture was then centrifuged to separate bound (remained with the beads) and unbound (remained in the supernatant) MBP-IL-1-R-1c. After extensive washing, the bound MBP-IL-1-R-1c was eluted with glutathione and detected by Western blot analysis using an MBP antibody. The IL-1-R-1c or the intracellular ligand can also be immobilized on other solid supports, such as on plates or fluorobeads. The binding can then be measured using ELISA or SPA (scintillation proximity assay).

EXAMPLE 4 CHARACTERIZATION OF IL-1-R INTRACELLULAR LIGAND PROTEIN

Mapping the interaction site in IL-1-R-1c

Many of the key amino acids for IL-1-R signaling have been determined by site-directed mutagenesis (Heguy et al., 1992, JBC, 267, 2605-2609). These amino acids are conserved between IL-1-R and the Drosophila Toll protein, which is required for transducing dorsoventral positional information to cells in the developing embryo. In order to test if the IL-1-R intracellular proteins interact with these residues, these residues were mutagenized and the ability of the mutant protein to interact with the intracellular ligand in the "interaction trap" system was tested. Mutations that abolish IL-1R signaling were introduced into the original bait plasmid,

EG202-IL-1R (477-527) (with following amino acid substitutions: F513A, W514A, K515R, R518K, and Y519S) and the ability of the IL-1R intracellular ligands to interact with these mutant proteins was tested in the interaction trap. EGY48 carrying pSH18-34 (lexAop-LacZ) were cotransformed with two plasmids: one carrying 14w, 19w or 31w; the other with bait, EG202-IL1R (477-527), either wild-type or one of the mutants. transformants were then streaked onto CM ura⁻his⁻trp⁻ plates containing galactose/raffinose and β -gal. The strength of interaction (as indicated by the number of "+" signs) was judged by the blueness in the plates (indicator of LacZ expression). The results are summarized in Table I.

10

Table I

bait →	WT	F513A	W514A	K515R	R518K	Y519S
clone ↓						
14w	+++	++	+	+++	+++	+
19w	+	-	+	++	-	-
31w	++	-	-	+++	-	-

15

Clone 14w interacted with mutant baits W514A and Y519S much more weakly than with wild-type bait. Clone 19w interacted differentially with wild-type and many of the mutant baits. It appeared to interact with the mutant bait K515R more strongly than with wild-type, while reduced interaction was observed with mutant baits F513R, R518K and Y519S. The interaction of clone 31w was significantly reduced by mutations F513A, W514A, R518K and Y519S. The change in the interaction strength by these mutations suggests that these residues are the site(s) of interaction. therefore, these data suggest that clones 14w, 19w and 31w interact with many of the signaling residues and may play a role in IL-1R signaling.

25

Effect on the IL-1-mediated response

The effect of the IL-1-R intracellular ligands on the IL-1-mediated response can be evaluated in cells overexpressing the ligands. A number of IL-1 mediated

30

responses, including transient or prolonged responses, can be measured. For example, IL-1-induced kinase activity toward either MBP (myelin basic protein) or the N-terminus (amino acids 1-79) of c-jun can be measured in COS cells or CHO cells either transiently or stably overexpressing IL-1R intracellular ligand proteins.

5 Alternatively, other functional assays, such as the induction of gene expression or PGE₂ production after prolonged incubation with IL-1, can also be used to measure the IL-1 mediated response. Conversely, the significance of the IL-1-R intracellular ligand proteins in IL-1 signaling can be established by lowering or eliminating the expression of the ligands. These experiments can be performed using antisense

10 expression or transgenic mice.

IL-1 mediated JNK (c-jun NH₂-terminal kinase, Derjard et al., Cell 1994, 76, 1025-1037) activation was used to study the effect of the IL-1R intracellular ligands on IL-1 signaling. COS cells were transfected with both pEDflag plasmid containing one of the clones (e.g., 19w) and HA-JNK1 plasmid by the DEAE-dextran method.

15 48 hrs after transfection, cells were starved in 0.1% BSA for 1 hr and treated with various amounts of IL-1 α for 15 min. Cells were then lysed, centrifuged and immunoprecipitated with anti-HA monoclonal antibody, 12CA5 (Boehringer Mannheim). JNK activity was performed at 30°C for 20 min using 5 μ g GST-c-jun (1-79 amino acids), 20 μ M ATP, and 5 μ Ci [γ -³²P]ATP in 40 μ l of kinase buffer (25

20 mM HEPES, pH 7.5, 20 mM MgCl₂, 20 mM β -glycerophosphate, 0.1 mM sodium orthovanadate, 2 mM DTT). The reactions were terminated using laemmli sample buffer and the products were resolved by SDS-PAGE (4-20%).

As shown in Fig. 2, expression of clone 19w stimulated JNK activity in all IL-1 concentrations tested as compared to the pED flag vector transfected cells. It

25 also enhanced JNK activity even in the absence of IL-1. These data strongly suggest that clone 19w, through its interaction with the signaling domain of IL-1 receptor (*i.e.*, amino acids 477-527 of IL-1R), may indeed participate in the signaling event.

Enzymatic or functional assays

30 The signal transduction events initiated by IL-1 binding to its-receptor are still largely unknown. However, one major result of IL-1 binding is the stimulation of cellular serine/threonine kinase activity. In addition, IL-1 has been shown to stimulate

the activity of PC-PLC, PLA₂, and sphingomyelinase. Therefore, some of the IL-1-R intracellular ligand proteins may possess intrinsic enzymatic activity that is responsible for these activities. Therefore, enzymatic assays can be performed to test this possibility, particularly with those clones that encode proteins with sequence
5 homology to known enzymes. In addition to enzymatic activity, based on the sequence homology to proteins with known function, other functional assays, for instance, ATP binding/transporter activity for the full length protein of clone 140, can also be measured.

10

EXAMPLE 5 ISOLATION OF FULL LENGTH CLONES

In many cases, cDNAs obtained from the interaction trap method each encode only a portion of the full length protein. Therefore, it is desirable to isolate full
15 length clones. The cDNAs obtained from the screening are used as probes, and the cDNA libraries described herein, or alternatively phage cDNA libraries, are screened to obtain full length clones in accordance with known methods (see for example, "Molecular Cloning, A Laboratory Manual", by Sambrook et al., 1989 Cold Spring Harbor).

20

EXAMPLE 6 ANTIBODIES SPECIFIC FOR IL-1-R INTRACELLULAR LIGAND PROTEIN

25 Antibodies specific for IL-1-R intracellular ligand proteins can be produced using purified recombinant protein, as described in Example 2, as antigen. Both polyclonal and monoclonal antibodies will be produced using standard techniques, such as those described in "Antibodies, a Laboratory Manual" by Ed Harlow and David Lane (1988), Cold Spring Harbor Laboratory.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Lin, Lih-Ling
Graham, James
- (ii) TITLE OF INVENTION: NOVEL INTERLEUKIN-1 RECEPTOR
INTRACELLULAR LIGAND PROTEINS AND INHIBITORS OF LIGAND
BINDING
- (iii) NUMBER OF SEQUENCES: 7
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: LEGAL AFFAIRS, GENETICS INSTITUTE, INC.
 - (B) STREET: 87 CambridgePark Drive
 - (C) CITY: Cambridge
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02140
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Brown, Scott A.
 - (B) REGISTRATION NUMBER: 32,724
 - (C) REFERENCE/DOCKET NUMBER: GI5258
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (617) 498-8224
 - (B) TELEFAX: (617) 876-5851

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1571 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 2..529

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

G ATC CCC AGG GTG GAC CTC CGG GTG TGG CAG GAC TGC TGT GAA GAC
 Ile Pro Arg Val Asp Leu Arg Val Trp Gln Asp Cys Cys Glu Asp
 1 5 10 15

46

TGT AGG ACC AGG GGG CAG TTC AAT GCC TTT TCC TAT CAT TTC CGA GGC Cys Arg Thr Arg Gly Gln Phe Asn Ala Phe Ser Tyr His Phe Arg Gly	94
20 25 30	
AGA CGG TCT CTT GAG TTC AGC TAC CAG GAG GAC AAG CCG ACC AAG AAA Arg Arg Ser Leu Glu Phe Ser Tyr Gln Glu Asp Lys Pro Thr Lys Lys	142
35 40 45	
ACA AGA CCA CGG AAA ATA CCC AGT GTT GGG AGA CAG GGG GAA CAT CTC Thr Arg Pro Arg Lys Ile Pro Ser Val Gly Arg Gln Gly Glu His Leu	190
50 55 60	
AGC AAC AGC ACC TCA GCC TTC AGC ACA CGC TCA GAT GCA TCT GGG ACA Ser Asn Ser Thr Ser Ala Phe Ser Thr Arg Ser Asp Ala Ser Gly Thr	238
65 70 75	
AAT GAC TTC AGA GAG TTT GTT CTG GAA ATG CAG AAG ACC ATC ACA GAC Asn Asp Phe Arg Glu Phe Val Leu Glu Met Gln Lys Thr Ile Thr Asp	286
80 85 90 95	
CTC AGA ACA CAG ATA AAG AAA CTT GAA TCA CGG CTC AGT ACC ACA GAG Leu Arg Thr Gln Ile Lys Lys Leu Glu Ser Arg Leu Ser Thr Thr Glu	334
100 105 110	
TGC GTG GAT GCC GGG GGC GAA TCT CAC GCC AAC AAC ACC AAG TGG AAA Cys Val Asp Ala Gly Gly Glu Ser His Ala Asn Asn Thr Lys Trp Lys	382
115 120 125	
AAA GAT GCA TGC ACC ATT TGT GAA TGC AAA GAC GGG CAG GTC ACC TGC Lys Asp Ala Cys Thr Ile Cys Glu Cys Lys Asp Gly Gln Val Thr Cys	430
130 135 140	
TTC GTG GAA GCT TGC CCC CCT GCC ACC TGT GCT GTC CCC GTG AAC ATC Phe Val Glu Ala Cys Pro Pro Ala Thr Cys Ala Val Pro Val Asn Ile	478
145 150 155	
CCA GGG GCC TGC TGT CCA GTC TGC TTA CAG AAG AGG GCG GAG GAA AAG Pro Gly Ala Cys Cys Pro Val Cys Leu Gln Lys Arg Ala Glu Glu Lys	526
160 165 170 175	
CCC TAGGCTCCTG GGAGGCTCCT CAGAGTTTGT CTGCTGTGCC ATCGTGAGAT Pro	579
CGGGTGGCCG ATGGCAGGGA GCTGCGGACT GCAGACCCGG AACACCCAG AACTCGTGAC	639
ATTTTCATGAC AACGTCCAGC TGGTGCTGTT ACAGAAGGCA GTGCAGGAGG CTTCCAACCA	699
GAGCATCTGC GGAGAAGGAG GCACAGCAGG TGCCTGAAGG GAAGCAGGCA GGACTCCTAG	759
CTTCACGTTA GACTTCTCAG GTTTTTATTT AATTCTTTTA AAATGAAAAA TTGGTGCTAC	819
TATTAAATTG CACAGTTGAA TCATTTAGGC GCCTAAATTG ATTTTGCCTC CCAACACCAT	879
TTCTTTTTTAA ATAAAGCAGG ATACCTCTAT ATGTCAGCCT TGCCTTGTTT AGATGCCAGG	939
AGCCGGCAGA CCTGTCACCC GCAGGTGGGG TGACTCTCGG AGCTGCCAGA GGGGCTCACC	999
GAAATCGGGG TTCCATCACA AGCTATGTTT AAAAAGAAAA TTGGTGTTTG CCAACCGGAA	1059
CAGAACCTTT GATGAGAGCG TTCACAGGGA CACTGTCTGG GGGTGCACTG CAAAGCCCCG	1119
GCCTCTTCCC TGGGAACCTC TGAACCTCTC CTTCTCTGG GCTCTCTGTA ACATTTCACC	1179
ACACGTCAGC ATCTAATCCC AAGACAAACA TTCCCGCTGC TCGAAGCAGC TGTATAGCCT	1239
GTGACTCTCC GTGTGTCAGC TCCTTCCACA CCTGATTAGA ACATTCATAA GCCACATTTA	1299

GAAACAGGTT TGCTTTTCAGC TGTCACCTGC ACACATACTG CCTAGTTGTG AACCAAATGT 1359
 GAAAAAACCT CCTTCATCCC ATTGTGTATC TGATACCTGC CGAGGGCCAA GGGTGTGTGT 1419
 TGACAACGCC GCTCCCAGCC GGCCCTGGTT GCGTCCACGT CCTGAACAAG AGCCGCTTCC 1479
 GGATGGCTCT TCCCAAGGGA GGAGGAGCTC AAGTGTCTGG AACTGTCTAA CTTCAGGTTG 1539
 TGTGAGTGCG TTAAAAAAA AAAAAAAAAA AA 1571

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 176 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ile Pro Arg Val Asp Leu Arg Val Trp Gln Asp Cys Cys Glu Asp Cys
 1 5 10 15
 Arg Thr Arg Gly Gln Phe Asn Ala Phe Ser Tyr His Phe Arg Gly Arg
 20 25 30
 Arg Ser Leu Glu Phe Ser Tyr Gln Glu Asp Lys Pro Thr Lys Lys Thr
 35 40 45
 Arg Pro Arg Lys Ile Pro Ser Val Gly Arg Gln Gly Glu His Leu Ser
 50 55 60
 Asn Ser Thr Ser Ala Phe Ser Thr Arg Ser Asp Ala Ser Gly Thr Asn
 65 70 75 80
 Asp Phe Arg Glu Phe Val Leu Glu Met Gln Lys Thr Ile Thr Asp Leu
 85 90 95
 Arg Thr Gln Ile Lys Lys Leu Glu Ser Arg Leu Ser Thr Thr Glu Cys
 100 105 110
 Val Asp Ala Gly Gly Glu Ser His Ala Asn Asn Thr Lys Trp Lys Lys
 115 120 125
 Asp Ala Cys Thr Ile Cys Glu Cys Lys Asp Gly Gln Val Thr Cys Phe
 130 135 140
 Val Glu Ala Cys Pro Pro Ala Thr Cys Ala Val Pro Val Asn Ile Pro
 145 150 155 160
 Gly Ala Cys Cys Pro Val Cys Leu Gln Lys Arg Ala Glu Glu Lys Pro
 165 170 175

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1088 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 2..961

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

G AAA AAA GGA GGT AAA ACA GAA CAG GAT GGC TAT CAG AAA CCC ACC	46
Lys Lys Gly Gly Lys Thr Glu Gln Asp Gly Tyr Gln Lys Pro Thr	
1 5 10 15	
AAC AAA CAC TTC ACG CAG AGT CCC AAG AAG TCA GTG GCC GAC CTG CTG	94
Asn Lys His Phe Thr Gln Ser Pro Lys Lys Ser Val Ala Asp Leu Leu	
20 25 30	
GGG TCC TTT GAA GGC AAA CGA AGA CTC CTT CTG ATC ACT GCT CCC AAG	142
Gly Ser Phe Glu Gly Lys Arg Arg Leu Leu Ile Thr Ala Pro Lys	
35 40 45	
GCT GAG AAC AAT ATG TAT GTG CAA CAA CGT GAT GAA TAT CTG GAA AGT	190
Ala Glu Asn Asn Met Tyr Val Gln Gln Arg Asp Glu Tyr Leu Glu Ser	
50 55 60	
TTC TGC AAG ATG GCT ACC AGG AAA ATC TCT GTG ATC ACC ATC TTC GGC	238
Phe Cys Lys Met Ala Thr Arg Lys Ile Ser Val Ile Thr Ile Phe Gly	
65 70 75	
CCT GTC AAC AAC AGC ACC ATG AAA ATC GAC CAC TTT CAG CTA GAT AAT	286
Pro Val Asn Asn Ser Thr Met Lys Ile Asp His Phe Gln Leu Asp Asn	
80 85 90 95	
GAG AAG CCC ATG CGA GTG GTG GAT GAT GAA GAC TTG GTA GAC CAG CGT	334
Glu Lys Pro Met Arg Val Val Asp Asp Glu Asp Leu Val Asp Gln Arg	
100 105 110	
CTC ATC AGC GAG CTG AGG AAA GAG TAC GGA ATG ACC TAC AAT GAC TTC	382
Leu Ile Ser Glu Leu Arg Lys Glu Tyr Gly Met Thr Tyr Asn Asp Phe	
115 120 125	
TTC ATG GTG CTA ACA GAT GTG GAT CTG AGA GTC AAG CAA TAC TAT GAG	430
Phe Met Val Leu Thr Asp Val Asp Leu Arg Val Lys Gln Tyr Tyr Glu	
130 135 140	
GTA CCA ATA ACA ATG AAG TCT GTG TTT GAT CTG ATC GAT ACT TTC CAG	478
Val Pro Ile Thr Met Lys Ser Val Phe Asp Leu Ile Asp Thr Phe Gln	
145 150 155	
TCC CGA ATC AAA GAT ATG GAG AAG CAG AAG AAG GAG GGC ATT GTT TGC	526
Ser Arg Ile Lys Asp Met Glu Lys Gln Lys Lys Glu Gly Ile Val Cys	
160 165 170 175	
AAA GAG GAA GTT GGG GGA GTG TTA GAA CTG TTC CCA ATT AAT GGG AGC	574
Lys Glu Glu Val Gly Gly Val Leu Glu Leu Phe Pro Ile Asn Gly Ser	
180 185 190	
TCT GTT GTT GAG CGA GAA GAC GTA CCA GCC CAT TTG GTG AAA GAC ATT	622
Ser Val Val Glu Arg Glu Asp Val Pro Ala His Leu Val Lys Asp Ile	
195 200 205	
CGT AAC TAT TTT CAA GTG AGC CCG GAG TAC TTC TCC ATG CTT CTA GTC	670
Arg Asn Tyr Phe Gln Val Ser Pro Glu Tyr Phe Ser Met Leu Leu Val	
210 215 220	
GGA AAA GAC GGA AAT GTC AAA TCC TGG TAT CCT TCC CCA ATG TGG TCC	718
Gly Lys Asp Gly Asn Val Lys Ser Trp Tyr Pro Ser Pro Met Trp Ser	
225 230 235	

ATG GTG ATT GTG TAC GAT TTA ATT GAT TCG ATG CAA CTT CGG AGA CAG 766
 Met Val Ile Val Tyr Asp Leu Ile Asp Ser Met Gln Leu Arg Arg Gln 255
 240 245 250
 GAA ATG GCG ATT CAG CAG TCA CTG GGG ATG CGC TGC CAG AAG ATG AGT 814
 Glu Met Ala Ile Gln Gln Ser Leu Gly Met Arg Cys Gln Lys Met Ser 270
 260 265
 ATG CAG GCT ATG GTT ACC ATA GTT ACC ACC AAG GAT ACC AGG ATG GTT 862
 Met Gln Ala Met Val Thr Ile Val Thr Thr Lys Asp Thr Arg Met Val 285
 275 280
 ACC AGG ATG ACT ACC GTC ATC ATG AGA GTT ATC ACC ATG GAT ACC CTT 910
 Thr Arg Met Thr Thr Val Ile Met Arg Val Ile Thr Met Asp Thr Leu 300
 290 295
 ACT GAG CAG AAA TAT GTA ACC TTA GAC TCA GCC AGT TTC CTC TGC AGC 958
 Thr Glu Gln Lys Tyr Val Thr Leu Asp Ser Ala Ser Phe Leu Cys Ser 315
 305 310
 TGC TAAACTACA TGTGGCCAGC TCCATTCTTC CACACTGCGT ACTACATTTT 1011
 Cys 320
 CTGCCTTTTTT CTTTCAGTGT TTTTCTAAGA CTAAATAAAT AGCAAACCTTT CACCTAAAAA 1071
 AAAAAAAAAA AAAAAA 1088

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 320 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Lys Lys Gly Gly Lys Thr Glu Gln Asp Gly Tyr Gln Lys Pro Thr Asn
 1 5 10 15
 Lys His Phe Thr Gln Ser Pro Lys Lys Ser Val Ala Asp Leu Leu Gly
 20 25 30
 Ser Phe Glu Gly Lys Arg Arg Leu Leu Ile Thr Ala Pro Lys Ala
 35 40 45
 Glu Asn Asn Met Tyr Val Gln Gln Arg Asp Glu Tyr Leu Glu Ser Phe
 50 55 60
 Cys Lys Met Ala Thr Arg Lys Ile Ser Val Ile Thr Ile Phe Gly Pro
 65 70 75 80
 Val Asn Asn Ser Thr Met Lys Ile Asp His Phe Gln Leu Asp Asn Glu
 85 90 95
 Lys Pro Met Arg Val Val Asp Asp Glu Asp Leu Val Asp Gln Arg Leu
 100 105 110
 Ile Ser Glu Leu Arg Lys Glu Tyr Gly Met Thr Tyr Asn Asp Phe Phe
 115 120 125
 Met Val Leu Thr Asp Val Asp Leu Arg Val Lys Gln Tyr Tyr Glu Val
 130 135 140

Pro Ile Thr Met Lys Ser Val Phe Asp Leu Ile Asp Thr Phe Gln Ser
 145 150 155 160
 Arg Ile Lys Asp Met Glu Lys Gln Lys Lys Glu Gly Ile Val Cys Lys
 165 170 175
 Glu Glu Val Gly Gly Val Leu Glu Leu Phe Pro Ile Asn Gly Ser Ser
 180 185 190
 Val Val Glu Arg Glu Asp Val Pro Ala His Leu Val Lys Asp Ile Arg
 195 200 205
 Asn Tyr Phe Gln Val Ser Pro Glu Tyr Phe Ser Met Leu Leu Val Gly
 210 215 220
 Lys Asp Gly Asn Val Lys Ser Trp Tyr Pro Ser Pro Met Trp Ser Met
 225 230 235 240
 Val Ile Val Tyr Asp Leu Ile Asp Ser Met Gln Leu Arg Arg Gln Glu
 245 250 255
 Met Ala Ile Gln Gln Ser Leu Gly Met Arg Cys Gln Lys Met Ser Met
 260 265 270
 Gln Ala Met Val Thr Ile Val Thr Thr Lys Asp Thr Arg Met Val Thr
 275 280 285
 Arg Met Thr Thr Val Ile Met Arg Val Ile Thr Met Asp Thr Leu Thr
 290 295 300
 Glu Gln Lys Tyr Val Thr Leu Asp Ser Ala Ser Phe Leu Cys Ser Cys
 305 310 315 320

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1759 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 2..1754

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

C AAA AAC TTC TTC CTG ACG AAT CGC GCC AGG GAG CGC TCA GAC ACC 46
 Lys Asn Phe Phe Leu Thr Asn Arg Ala Arg Glu Arg Ser Asp Thr
 1 5 10 15
 TTC ATC AAC CTC CGG GAG GTG CTC AAC CGC TTC AAG CTG CCG CCA GGA 94
 Phe Ile Asn Leu Arg Glu Val Leu Asn Arg Phe Lys Leu Pro Pro Gly
 20 25 30
 GAG TAC ATT CTC GTG CCT TCC ACC TTC GAA CCC AAC AAG GAT GGG GAT 142
 Glu Tyr Ile Leu Val Pro Ser Thr Phe Glu Pro Asn Lys Asp Gly Asp
 35 40 45

TTC	TGC	ATC	CGG	GTC	TTT	TCT	GAA	AAG	AAA	GCT	GAC	TAC	CAA	GCT	GTC	190
Phe	Cys	Ile	Arg	Val	Phe	Ser	Glu	Lys	Lys	Ala	Asp	Tyr	Gln	Ala	Val	
		50					55					60				
GAT	GAT	GAA	ATC	GAG	GCC	AAT	CTT	GAA	GAG	TTC	GAC	ATC	AGC	GAG	GAT	238
Asp	Asp	Glu	Ile	Glu	Ala	Asn	Leu	Glu	Glu	Phe	Asp	Ile	Ser	Glu	Asp	
		65				70					75					
GAC	ATT	GAT	GAT	GGA	TTC	AGG	AGA	CTG	TTT	GCC	CAG	TTG	GCA	GGA	GAG	286
Asp	Ile	Asp	Asp	Gly	Phe	Arg	Arg	Leu	Phe	Ala	Gln	Leu	Ala	Gly	Glu	
		80			85					90					95	
GAT	GCG	GAG	ATC	TCT	GCC	TTT	GAG	CTG	CAG	ACC	ATC	CTG	AGA	AGG	GTT	334
Asp	Ala	Glu	Ile	Ser	Ala	Phe	Glu	Leu	Gln	Thr	Ile	Leu	Arg	Arg	Val	
				100					105						110	
CTA	GCA	AAG	CGC	CAA	GAT	ATC	AAG	TCA	GAT	GGC	TTC	AGC	ATC	GAG	ACA	382
Leu	Ala	Lys	Arg	Gln	Asp	Ile	Lys	Ser	Asp	Gly	Phe	Ser	Ile	Glu	Thr	
			115					120						125		
TGC	AAA	ATT	ATG	GTT	GAC	ATG	CTA	GAT	TCG	GAC	GGG	AGT	GGC	AAG	CTG	430
Cys	Lys	Ile	Met	Val	Asp	Met	Leu	Asp	Ser	Asp	Gly	Ser	Gly	Lys	Leu	
		130					135					140				
GGG	CTG	AAG	GAG	TTC	TAC	ATT	CTC	TGG	ACG	AAG	ATT	CAA	AAA	TAC	CAA	478
Gly	Leu	Lys	Glu	Phe	Tyr	Ile	Leu	Trp	Thr	Lys	Ile	Gln	Lys	Tyr	Gln	
	145					150					155					
AAA	ATT	TAC	CGA	GAA	ATC	GAC	GTT	GAC	AGG	TCT	GGT	ACC	ATG	AAT	TCC	526
Lys	Ile	Tyr	Arg	Glu	Ile	Asp	Val	Asp	Arg	Ser	Gly	Thr	Met	Asn	Ser	
	160				165				170						175	
TAT	GAA	ATG	CGG	AAG	GCA	TTA	GAA	GAA	GCA	GGT	TTC	AAG	ATG	CCC	TGT	574
Tyr	Glu	Met	Arg	Lys	Ala	Leu	Glu	Glu	Ala	Gly	Phe	Lys	Met	Pro	Cys	
			180						185					190		
CAA	CTC	CAC	CAA	GTC	ATC	GTT	GCT	CGG	TTT	GCA	GAT	GAC	CAG	CTC	ATC	622
Gln	Leu	His	Gln	Val	Ile	Val	Ala	Arg	Phe	Ala	Asp	Asp	Gln	Leu	Ile	
			195					200					205			
ATC	GAT	TTT	GAT	AAT	TTT	GTT	CGG	TGT	TTG	GTT	CGG	CTG	GAA	ACG	CTA	670
Ile	Asp	Phe	Asp	Asn	Phe	Val	Arg	Cys	Leu	Val	Arg	Leu	Glu	Thr	Leu	
		210				215						220				
TTC	AAG	ATA	TTT	AAG	CAG	CTG	GAT	CCC	GAG	AAT	ACT	GGA	ACA	ATA	GAG	718
Phe	Lys	Ile	Phe	Lys	Gln	Leu	Asp	Pro	Glu	Asn	Thr	Gly	Thr	Ile	Glu	
	225					230					235					
CTC	GAC	CTT	ATC	TCT	TGG	CTC	TGT	TTC	TCA	GTA	CTT	TGAAGTTATA				764
Leu	Asp	Leu	Ile	Ser	Trp	Leu	Cys	Phe	Ser	Val	Leu					
	240				245					250						
ACTAATCTGC	CTGAAGACTT	CTCATGATGG	AAAATCAGCC	AAGGACTAAG	CTTCCATAGA											824
AATACACTTT	GTATCTGGAC	CTCAAAATTA	TGGGAACATT	TACTTAAACG	GATGATCATA											884
GCTGAAAATA	ATGATACTGT	CAATTTGAGA	TAGCAGAAGT	TTCACACATC	AAAGTAAAAG											944
ATTTGCATAT	CATTATACTA	AATGCAAATG	AGTCGCTTAA	CCCTTGACAA	GGTCAAAGAA											1004
AGCTTTAAAT	CTGTAAATAG	TATACACTTT	TTACTTTTAC	ACACTTTTCT	GTTCATAGCA											1064
ATATTAAATC	AGGAAAAAAA	AATGCAGGGA	GGTATTTAAC	AGCTGAGCAA	AAACATTGAG											1124
TCGCTCTCAA	AGGACACGAG	GCCCTTGGCA	GGGAATATTT	AAAGCAACTT	CAAGTTTAAA											1184
ATGCAGCTGT	TGATTCTACC	AAACAACAGT	CCAAGATTAC	CATTTCCCAT	GAGCCCACTG											1244

GGAAACATGG TATATCATGA AGTAATCTTG TCAAGGCATC TGGAGAGTCC AGGAGAGAAG 1304
 ACTCACCTCT GTCGCTTGGG TTAAACAAGA GACAGGTTTT GTAGAATATT GATTGGTAAT 1364
 AGTAAATCGT TCTCCTTACA ATCAAGTTCT TGACCCTATT CGGCCTTATA CATCTGGTCT 1424
 TACAAAGACC AAAGGGATCC TGCGCTTGAT CAACTGAACC AGTATGCCAA AACCAGGCAT 1484
 CCAATTTGTA AACCAATTAT GATAAAGGAC AAAATAAGCT GTTTGCCACC TCAAACTTT 1544
 ATGAACTTCA CCACCACTAG TGTCTGTCCA TGGAGTTAGA GGGGACATCA CTTAGAAGTT 1604
 CTTATAGAAA GGACACAAGT TTGTTTCCTG GCTTTACCTT GGGAAAATGC TAGCAACATT 1664
 ATAGAAATTT TGCCTTGTTG CTTATCTTC TTCCAAATGT ACTGTAAAT AAAAATAAAG 1724
 GGTTACCCCA TGCAATCAAA AAAAAAAAAA AAAAA 1759

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 251 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Lys Asn Phe Phe Leu Thr Asn Arg Ala Arg Glu Arg Ser Asp Thr Phe
 1 5 10 15
 Ile Asn Leu Arg Glu Val Leu Asn Arg Phe Lys Leu Pro Pro Gly Glu
 20 25 30
 Tyr Ile Leu Val Pro Ser Thr Phe Glu Pro Asn Lys Asp Gly Asp Phe
 35 40 45
 Cys Ile Arg Val Phe Ser Glu Lys Lys Ala Asp Tyr Gln Ala Val Asp
 50 55 60
 Asp Glu Ile Glu Ala Asn Leu Glu Glu Phe Asp Ile Ser Glu Asp Asp
 65 70 75 80
 Ile Asp Asp Gly Phe Arg Arg Leu Phe Ala Gln Leu Ala Gly Glu Asp
 85 90 95
 Ala Glu Ile Ser Ala Phe Glu Leu Gln Thr Ile Leu Arg Arg Val Leu
 100 105 110
 Ala Lys Arg Gln Asp Ile Lys Ser Asp Gly Phe Ser Ile Glu Thr Cys
 115 120 125
 Lys Ile Met Val Asp Met Leu Asp Ser Asp Gly Ser Gly Lys Leu Gly
 130 135 140
 Leu Lys Glu Phe Tyr Ile Leu Trp Thr Lys Ile Gln Lys Tyr Gln Lys
 145 150 155 160
 Ile Tyr Arg Glu Ile Asp Val Asp Arg Ser Gly Thr Met Asn Ser Tyr
 165 170 175
 Glu Met Arg Lys Ala Leu Glu Glu Ala Gly Phe Lys Met Pro Cys Gln
 180 185 190

Leu His Gln Val Ile Val Ala Arg Phe Ala Asp Asp Gln Leu Ile Ile
 195 200 205

Asp Phe Asp Asn Phe Val Arg Cys Leu Val Arg Leu Glu Thr Leu Phe
 210 215 220

Lys Ile Phe Lys Gln Leu Asp Pro Glu Asn Thr Gly Thr Ile Glu Leu
 225 230 235 240

Asp Leu Ile Ser Trp Leu Cys Phe Ser Val Leu
 245 250

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 700 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Ala Gly Ile Ala Ala Lys Leu Ala Lys Asp Arg Glu Ala Ala Glu
 1 5 10 15

Gly Leu Gly Ser His Glu Arg Ala Ile Lys Tyr Leu Asn Gln Asp Tyr
 20 25 30

Glu Ala Leu Arg Asn Glu Cys Leu Glu Ala Gly Thr Leu Phe Gln Asp
 35 40 45

Pro Ser Phe Pro Ala Ile Pro Ser Ala Leu Gly Phe Lys Glu Leu Gly
 50 55 60

Pro Tyr Ser Ser Lys Thr Arg Gly Met Arg Trp Lys Arg Pro Thr Glu
 65 70 75 80

Ile Cys Ala Asp Pro Gln Phe Ile Ile Gly Gly Ala Thr Arg Thr Asp
 85 90 95

Ile Cys Gln Gly Ala Leu Gly Asp Cys Trp Leu Leu Ala Ala Ile Ala
 100 105 110

Ser Leu Thr Leu Asn Glu Glu Ile Leu Ala Arg Val Val Pro Leu Asn
 115 120 125

Gln Ser Phe Gln Glu Asn Tyr Ala Gly Ile Phe His Phe Gln Phe Trp
 130 135 140

Gln Tyr Gly Glu Trp Val Glu Val Val Val Asp Asp Arg Leu Pro Thr
 145 150 155 160

Lys Asp Gly Glu Leu Leu Phe Val His Ser Ala Glu Gly Ser Glu Phe
 165 170 175

Trp Ser Ala Leu Leu Glu Lys Ala Tyr Ala Lys Ile Asn Gly Cys Tyr
 180 185 190

Glu Ala Leu Ser Gly Gly Ala Thr Glu Gly Phe Glu Asp Phe Thr
 195 200 205

Gly Gly Ile Ala Glu Trp Tyr Glu Leu Lys Lys Pro Pro Pro Asn Leu
 210 215 220
 Phe Lys Ile Ile Gln Lys Ala Leu Gln Lys Gly Ser Leu Leu Gly Cys
 225 230 235 240
 Ser Ile Asp Ile Thr Ser Ala Ala Asp Ser Glu Ala Ile Thr Phe Gln
 245 250 255
 Lys Leu Val Lys Gly His Ala Tyr Ser Val Thr Gly Ala Glu Glu Val
 260 265 270
 Glu Ser Asn Gly Ser Leu Gln Lys Leu Ile Arg Ile Arg Asn Pro Trp
 275 280 285
 Gly Glu Val Glu Trp Thr Gly Arg Trp Asn Asp Asn Cys Pro Ser Trp
 290 295 300
 Asn Thr Ile Asp Pro Glu Glu Arg Glu Arg Leu Thr Arg Arg His Glu
 305 310 315 320
 Asp Gly Glu Phe Trp Met Ser Phe Ser Asp Phe Leu Arg His Tyr Ser
 325 330 335
 Arg Leu Glu Ile Cys Asn Leu Thr Pro Asp Thr Leu Thr Ser Asp Thr
 340 345 350
 Tyr Lys Lys Trp Lys Leu Thr Lys Met Asp Gly Asn Trp Arg Arg Gly
 355 360 365
 Ser Thr Ala Gly Gly Cys Arg Asn Tyr Pro Asn Thr Phe Trp Met Asn
 370 375 380
 Pro Gln Tyr Leu Ile Lys Leu Glu Glu Glu Asp Glu Asp Glu Glu Asp
 385 390 395 400
 Gly Glu Ser Gly Cys Thr Phe Leu Val Gly Leu Ile Gln Lys His Arg
 405 410 415
 Arg Arg Gln Arg Lys Met Gly Glu Asp Met His Thr Ile Gly Phe Gly
 420 425 430
 Ile Tyr Glu Val Pro Glu Glu Leu Ser Gly Gln Thr Asn Ile His Leu
 435 440 445
 Ser Lys Asn Phe Phe Leu Thr Asn Arg Ala Arg Glu Arg Ser Asp Thr
 450 455 460
 Phe Ile Asn Leu Arg Glu Val Leu Asn Arg Phe Lys Leu Pro Pro Gly
 465 470 475 480
 Glu Tyr Ile Leu Val Pro Ser Thr Phe Glu Pro Asn Lys Asp Gly Asp
 485 490 495
 Phe Cys Ile Arg Val Phe Ser Glu Lys Lys Ala Asp Tyr Gln Ala Val
 500 505 510
 Asp Asp Glu Ile Glu Ala Asn Leu Glu Glu Phe Asp Ile Ser Glu Asp
 515 520 525
 Asp Ile Asp Asp Gly Val Arg Arg Leu Phe Ala Gln Leu Ala Gly Glu
 530 535 540
 Asp Ala Glu Ile Ser Ala Phe Glu Leu Gln Thr Ile Leu Arg Arg Val
 545 550 555 560

Leu Ala Lys Arg Gln Asp Ile Lys Ser Asp Gly Phe Ser Ile Glu Thr
565 570 575

Cys Lys Ile Met Val Asp Met Leu Asp Ser Asp Gly Ser Gly Lys Leu
580 585 590

Gly Leu Lys Glu Phe Tyr Ile Leu Trp Thr Lys Ile Gln Lys Tyr Gln
595 600 605

Lys Ile Tyr Arg Glu Ile Asp Val Asp Arg Ser Gly Thr Met Asn Ser
610 615 620

Tyr Glu Met Arg Lys Ala Leu Glu Glu Ala Gly Phe Lys Met Pro Cys
625 630 635 640

Gln Leu His Gln Val Ile Val Ala Arg Phe Ala Asp Asp Gln Leu Ile
645 650 655

Ile Asp Phe Asp Asn Phe Val Arg Cys Leu Val Arg Leu Glu Thr Leu
660 665 670

Phe Lys Ile Phe Lys Gln Leu Asp Pro Glu Asn Thr Gly Thr Ile Glu
675 680 685

Leu Asp Leu Ile Ser Trp Leu Cys Phe Ser Val Leu
690 695 700

CLAIMS

What is claimed is:

1. A composition comprising an isolated polynucleotide encoding a protein having IL-1-R intracellular ligand protein activity.
2. The composition of claim 1 wherein said polynucleotide is selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 2 to nucleotide 529;
 - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:1, which encodes a protein having IL-1-R intracellular ligand protein activity;
 - (c) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:2;
 - (d) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 and having IL-1-R intracellular ligand protein activity; and
 - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d), which encodes a protein having IL-1-R intracellular ligand protein activity.
3. The composition of claim 1 wherein said polynucleotide sequence is selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 2 to nucleotide 961;
 - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:3, which encodes a protein having IL-1-R intracellular ligand protein activity;
 - (c) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:4;

(d) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 and having IL-1-R intracellular ligand protein activity; and

(e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d), which encodes a protein having IL-1-R intracellular ligand protein activity.

4. The composition of claim 1 wherein said polynucleotide is selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 2 to nucleotide 754;

(b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:5, which encodes a protein having IL-1-R intracellular ligand protein activity;

(c) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:6;

(d) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 and having IL-1-R intracellular ligand protein activity; and

(e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d), which encodes a protein having IL-1-R intracellular ligand protein activity.

5. A composition comprising a protein having IL-1-R intracellular ligand protein activity.

6. The composition of claim 5 wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2; and

(b) fragments of the amino acid sequence of SEQ ID NO:2; said protein being substantially free from other mammalian proteins.

7. The composition of claim 5 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4; and
- (b) fragments of the amino acid sequence of SEQ ID NO:4;

said protein being substantially free from other mammalian proteins.

8. The composition of claim 5 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6; and
- (b) fragments of the amino acid sequence of SEQ ID NO:6;

said protein being substantially free from other mammalian proteins.

9. A composition of claim 1 wherein said polynucleotide is operably linked to an expression control sequence.

10. A host cell transformed with a composition of claim 9.

11. The host cell of claim 10, wherein said cell is a mammalian cell.

12. A process for producing an IL-1-R intracellular ligand protein, which comprises:

- (a) growing a culture of the host cell of claim 10 in a suitable culture medium; and
- (b) purifying the IL-1-R intracellular ligand protein from the culture.

13. A method of identifying an inhibitor of IL-1-R intracellular domain binding which comprises:

- (a) combining an IL-1-R intracellular domain protein with a composition of claim 5, said combination forming a first binding mixture;

(b) measuring the amount of binding between the IL-1-R intracellular domain protein and the IL-1-R intracellular ligand protein in the first binding mixture;

(c) combining a compound with the IL-1-R intracellular domain protein and an IL-1-R intracellular ligand protein to form a second binding mixture;

(d) measuring the amount of binding in the second binding mixture; and

(e) comparing the amount of binding in the first binding mixture with the amount of binding in the second binding mixture;

wherein the compound is capable of inhibiting IL-1-R intracellular domain binding when a decrease in the amount of binding of the second binding mixture occurs.

14. The method of claim 13 wherein said IL-1-R intracellular ligand protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) fragments of the amino acid sequence of SEQ ID NO:2;
- (c) the amino acid sequence of SEQ ID NO:4;
- (d) fragments of the amino acid sequence of SEQ ID NO:4;
- (e) the amino acid sequence of SEQ ID NO:6;
- (f) fragments of the amino acid sequence of SEQ ID NO:6;
- (g) the amino acid sequence of SEQ ID NO:7; and
- (h) fragments of the amino acid sequence of SEQ ID NO:7.

15. A method of identifying an inhibitor of IL-1-R intracellular domain binding which comprises:

- (a) transforming a cell with a first polynucleotide encoding an IL-1-R intracellular domain protein, a second polynucleotide encoding an IL-1-R intracellular ligand protein, and at least one reporter gene, wherein the expression of the reporter gene is regulated by the binding of the IL-1-R intracellular ligand protein encoded by the second polynucleotide to the IL-1-R intracellular domain protein encoded by the first polynucleotide;

(b) growing the cell in the presence of and in the absence of a compound; and

(c) comparing the degree of expression of the reporter gene in the presence of and in the absence of the compound;

wherein the compound is capable of inhibiting IL-1-R intracellular domain binding when a decrease in the degree of expression of the reporter gene occurs.

16. The method of claim 15 wherein the second polynucleotide is selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 2 to nucleotide 529;

(b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:1, which encodes a protein having IL-1-R intracellular ligand protein activity;

(c) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:2;

(d) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 and having IL-1-R intracellular ligand protein activity;

(e) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 2 to nucleotide 961;

(f) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:3, which encodes a protein having IL-1-R intracellular ligand protein activity;

(g) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:4;

(h) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 and having IL-1-R intracellular ligand protein activity;

(i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 2 to nucleotide 754;

(j) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:5, which encodes a protein having IL-1-R intracellular ligand protein activity;

(k) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:6;

(l) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 and having IL-1-R intracellular ligand protein activity;

(m) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising the amino acid sequence of SEQ ID NO:7;

(n) a polynucleotide encoding an IL-1-R intracellular ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 and having IL-1-R intracellular ligand protein activity; and

(o) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(n), which encodes a protein having IL-1-R intracellular ligand protein activity.

17. A composition comprising an antibody which specifically reacts with the IL-1-R intracellular ligand protein of claim 5.

18. The composition of claim 5, further comprising a pharmaceutically acceptable carrier.

19. A method of preventing or ameliorating an inflammatory condition which comprises administering a therapeutically effective amount of a composition of claim 18.

20. A method of inhibiting IL-1-R intracellular domain binding comprising administering a therapeutically effective amount of a composition of claim 18.

21. IL-1-R intracellular ligand protein produced according to the method of claim 12.

22. A composition comprising an inhibitor identified according to the method of claim 15.

23. The composition of claim 22 further comprising a pharmaceutically acceptable carrier.

24. A method of preventing or ameliorating an inflammatory condition comprising administering to a mammalian subject a therapeutically effective amount of the composition of claim 23.

25. A method of inhibiting IL-1-R intracellular domain binding comprising administering to a mammalian subject a therapeutically effective amount of the composition of claim 23.

Fig. 1




Fig. 2A




Fig. 2B





Fig. 2C



INTERNATIONAL SEARCH REPORT

National Application No
PCT/US 96/06363

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/11 C07K14/47 A61K38/17 C07K16/18 C12N9/64

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL Database entry HS17371 Accession number T98173; 16 April 1995 Hillier, L. ET AL. : XP002015168 "The WashU-Merck EST Project" see abstract	1,2
X	EMBL Database entry HS97641 Accession number T69976; 11 March 1995 Hillier, L. ET AL.: XP002015169 "WashU-Merck EST Project" see abstract	1,2



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

* & * document member of the same patent family

Date of the actual completion of the international search

8 October 1996

Date of mailing of the international search report

23. 10. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Hix, R

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/06363

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL Database entry HS46125 Accession number T54461; 28 February 1995 Hillier, L. ET AL. : XP002015170 "WashU-Merck EST Project" see abstract ---	1,2
X,P	WO,A,95 33819 (MITOTIX INC) 14 December 1995 see the whole document ---	1,3, 9-12,21
X	EMBL Database entry HS26829 Accession number T59268; 4 March 1995 Hillier, L. ET AL. : XP002015171 "WashU-Merck EST Project" see abstract ---	1,3
X	EMBL Database entry HS22728 Accession number T59227; 4 March 1995 Hillier, L. ET AL. : XP002015172 "WashU-Merck EST Project" see abstract ---	1,3
X	BIOCHEMISTRY, vol. 27, 1988, pages 8122-8128, XP002015165 S. IMAJOH ET AL.: "Molecular cloning of the cDNA for the large subunit of the high-Ca ²⁺ -requiring form of human Ca ²⁺ -activated neutral protease." cited in the application see the whole document ---	1,4
X	THE JOURNAL OF BIOLOGICAL CHEMISTRY , vol. 261, no. 20, 15 July 1986, pages 9465-9471, XP002015164 Y. EMORI ET AL.: "Isolation and sequence analyses of cDNA clones for the large subunits of two isozymes of rabbit calcium-dependent protease." see the whole document ---	1,4
X	BIOCHEMICA ET BIOPHYSICA ACTA, vol. 1216, 1993, pages 81-93, XP000603662 C.I. DELUCA ET AL.: "Molecular cloning and bacterial expression of cDNA for rat calpain II 80kDa subunit." see the whole document ---	1,4,9, 10,12,21

-/--

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 96/06363

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL Database entry, Accession no. S10590 Sorimachi, H. ET AL.: XP002015173 "A novel member of the calcuim-dependent cysteine protease family" see abstract ---	1,4
A	BIOCHEM J 273 (1). 1991. 79-83. CODEN: BIJOAK ISSN: 0306-3275, XP002015166 HORUK R: "DIFFERENCES IN INTERNALIZATION AND INTRACELLULAR PROCESSING OF INTERLEUKIN - 1 ASSOCIATED WITH THE TWO FORMS OF INTERLEUKIN - 1 RECEPTOR FOUND IN B-CELLS AND T-CELLS." see the whole document ---	1-25
A	JOURNAL OF EXPERIMENTAL MEDICINE 180 (4). 1994. 1321-1328. ISSN: 0022-1007, XP002015167 MCKEAN D J ET AL: "Ligand -induced desensitization of interleukin 1 receptor -initiated intracellular signaling events in T helper lymphocytes." see the whole document -----	1-25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/06363

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 19, 20, 24, 25
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 19, 20, 24, 25 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/ composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

